News Archive

LU Bio has decided to close the portfolio company Auril

Share
| Print |
Tell a colleague

Tell a colleague about this

Your name
Recipient E-mail

LU Bio has together with the inventors decided that the Auril project shall return from development phase back to research phase. There is a need to gain further insight and understanding of the temperature regulating mechanisms to be able to prepare for a clinical trial application. LU Bio has transferred all the IPR to the inventors and has closed the portfolio company.